Navigation Links
Convergence Pharmaceuticals Announces Successful Completion of Phase I for CNV2197944 and Plans Phase II Studies in Neuropathic Pain
Date:7/18/2012

CAMBRIDGE, England, July 18, 2012 /PRNewswire/ --

Phase I study data indicates CNV2197944's optimal profile for a chronic pain medication

Convergence Pharmaceuticals Limited ("Convergence"), the company focused on the development of novel and high value analgesic medicines for the treatment of chronic pain, today announces that it is designing Phase II proof of concept studies with CNV2197944 in neuropathic pain, following successful completion of Phase I. This novel, small molecule, state-dependent calcium channel blocker, is designed to selectively inhibit highly active Cav2.2 channels. It is the only truly selective Cav2.2 blocker in clinical development and has the potential to be a first in class treatment for chronic pain. Convergence is conducting the development of CNV2197944 on behalf of Calchan Ltd.

Results of the Phase I, placebo-controlled, multiple ascending dose clinical study with orally administered CNV2197944, demonstrated that the drug was well tolerated in all subjects, with few adverse events reported at doses that are expected to fall within the predicted therapeutic range. The compound was also well absorbed following oral administration, with a pharmacokinetic profile that is predictable and consistent in both young and elderly subjects.  These characteristics indicate CNV2197944's optimal profile for a chronic pain medication.

In view of these favourable data, well powered Phase II proof of concept trials for CNV2197944 in neuropathic pain are now being planned.

CNV2197944 - a first in class molecule with potential to be a first in class treatment

CNV2197944 is a novel, small molecule, state-dependent calcium channel blocker, designed to selectively inhibit highly active Cav2.2 channels. Preclinical studies demonstrated that CNV2197944 could have analgesic potential for a broad range of chronic pain conditions. Extensive safety and toxicology studies to support the clinical development of CNV2
'/>"/>

SOURCE Convergence Pharmaceuticals Ltd
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. The Convergence of Art, Science and Beer
2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
3. Oramed Pharmaceuticals Granted 2nd Patent in New Zealand; 3rd Patent for Core Technology on Oral Delivery of Proteins
4. Keryx Biopharmaceuticals to Present at The 7th Annual JMP Securities Healthcare Conference
5. Auxilium Pharmaceuticals, Inc. to Present At The JMP Securities 2012 Healthcare Conference
6. Access Pharmaceuticals to Report New MuGard Clinical Trial Data This Week at the MASCC/ISOO Symposium in New York City
7. Keryx Biopharmaceuticals Announces Live Webcast of Upcoming Analyst Day
8. Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
9. Questcor Pharmaceuticals to Present at Jefferies 2012 Global Healthcare Conference
10. Questcor Pharmaceuticals Expands Repurchase Program
11. Eutropics Pharmaceuticals Receives U.S. Patent for Novel Diagnostic Method
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... 17, 2015 CIO Review ( http://www.cioreview.com ... 20 Most Promising Pharma and Life Science Technology Solution ... global compliance software platform for life sciences companies. ... a panel of experts and members of CIO Review’s ... MediSpend Platform has been on our radar for some ...
(Date:4/17/2015)... 17, 2015  Guggenheim Securities, the investment banking and ... hiring of William Tanner as a Managing ... Tanner will start work at Guggenheim in May 2015 ... office. "Bill brings a wealth of biotech ... experienced and highly acclaimed healthcare team," said Matthew ...
(Date:4/17/2015)... 17, 2015 Global Stem Cells ... Stem Cell Summit 2015 April 27 - 29, 2015 ... developments in all areas of stem cell research including ... cells and regenerative medicine. , The conference will ... well as translational research in stem cell therapies, regenerative ...
(Date:4/17/2015)... BellBrook Labs announced today that they ... powerful Orthogonal Pooled Screening (OPS) Platform developed and ... Lankenau Institute for Medical Research (LCGC) in Wynnewood, ... successful drug discovery outcomes using far more efficient ... available nowhere else, coupled to a state-of-the-art compound ...
Breaking Biology Technology:MMIS Chosen by CIO Review as Top 20 Most Promising Pharma and Life Science Technology Solution Providers 2015 2Guggenheim Securities Hires Biotech Analyst William Tanner in Expansion of Healthcare Coverage 2Global Stem Cells Group To Join GTCbio Stem Cell and Regenerative Medicine Summit in Boston, April 27-29, 2015 2Global Stem Cells Group To Join GTCbio Stem Cell and Regenerative Medicine Summit in Boston, April 27-29, 2015 3BellBrook Labs and Lankenau Institute Partner to Accelerate Drug Discovery using Orthogonal Pooled Screening 2
... Pa., Oct. 2 /PRNewswire/ - Respironics, Inc. (Nasdaq:,RESP) ... the outstanding shares,of Apollo Light Systems, Inc., a ... light therapy systems for melatonin suppression and,circadian rhythm ... company is located in American Fork, Utah and ...
... Oct. 2 Monitorforhire.com, the,fastest source for ... even faster. The company has added a ... respond immediately to work requests via,PDA or ... Scott Freedman, president of monitorforhire.com says that ...
... Oct. 2 454 Life Sciences, a Roche,company, ... to,conduct large scale genetic re-sequencing in hundreds of ... responses to a widely,prescribed class of drug. The ... sufficient genetic variation can be identified and,validated to ...
Cached Biology Technology:Respironics Acquires Apollo Light Systems, Inc., Expands into Circadian Rhythm Device-Based Therapy Market 2Respironics Acquires Apollo Light Systems, Inc., Expands into Circadian Rhythm Device-Based Therapy Market 3New Pharmacogenomic Approach: 454 Life Sciences and Perlegen to Collaborate in Drug Response Sequencing Study 2New Pharmacogenomic Approach: 454 Life Sciences and Perlegen to Collaborate in Drug Response Sequencing Study 3
(Date:3/20/2015)... 20, 2015 Research and Markets ... the "India Sensors Market Forecast and Opportunities ... The sensor market is projected to grow at ... Consumer electronics, automotive, industrial and healthcare sectors are ... country. In addition, adoption of MEMS technology in ...
(Date:3/20/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ) has announced ... Business Report" report to their offering. This ... Thousands. The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... America . Annual estimates and forecasts are ...
(Date:3/17/2015)... March 17, 2015 MedNet Solutions ... in clinical study management systems, is pleased to ... at ARENA,s Outsourcing in Clinical Trials Southeast conference ... provides an excellent forum for MedNet to showcase ... affordable software-as-a-service (SaaS) eClinical technology platform. ...
Breaking Biology News(10 mins):India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2
... Spanish . Innovative, kid-friendly strategies ... skillsare emerging from scientific studies funded by the Agricultural ... Johnston, John P. Foreyt and Chermaine Tyler and their ... in which many of their Texas middle-school participants achieved ...
... in the 1990s the hole in Earth,s protective ... acid rain worse, scientists are reporting. Their study ... once used in aerosol spray cans, air conditioners, refrigerators, ... Physical Chemistry A , a weekly publication. Jeffrey ...
... Scientists at L,Oral, in hot pursuit of the hidden elements of ... "beauty is only skin deep." In fact, their work indicates that ... is much deeper. It actually is linked to molecules within the ... (C&EN), ACS, weekly newsmagazine. C&EN Senior Editor Lisa M. ...
Cached Biology News:Kids lose pounds, gain fitness in Houston study 2
Porcine parvovirus and mycoplasma tested. Contains 0.5 g/L of trypsin (1:250) and 0.2 g/L of EDTA4Na in Hanks' Balanced Salt Solution without CaCl2 MgCl2 6H2O and MgSO4 7H2O. Contains phenol red....
...
...
... P Set from different Cynomolgus monkey ... organs maybe available upon request. ... from the whole set, and pay ... All Dr. P Set products ...
Biology Products: